Loading...
NPI 1841798667 · Homewood, AL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Devansh Lab Werks,inc is a clinical medical laboratory provider located in Homewood, Alabama. This profile covers 96 Medicare and 127 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Devansh Lab Werks,inc |
| Address | 234 Aquarius Dr Ste 111 |
| City | Homewood |
| State | AL |
| ZIP | 35209 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 26, 2018 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $5.9M |
| Medicare | $1.9M |
Business mix centers on high-complexity toxicology and molecular infectious disease testing: Medicare top-revenue code G0483 (2K claims, $242 avg paid/claim, $480.4K revenue) and Medicaid leaders U0004 (29K claims, $53 avg paid/claim, $1.5M revenue) and 87798 (9.4K claims, $85 avg paid/claim, $795.2K revenue) indicate the lab performs large volumes of definitive multi‑class drug testing and high-throughput SARS‑CoV‑2/NAAT work, underscoring an operational focus on both toxicology and molecular diagnostics rather than routine outpatient chemistry alone.
Revenue concentration is meaningfully focused in a few codes for both payers: the top three Medicare codes account for 43.1% of this provider’s total Medicare revenue, while the top three Medicaid codes account for 55.2% of its total Medicaid revenue, showing that a small set of high-value tests disproportionately drives overall billing across both payers.
Payer mix is skewed toward Medicaid by scale: lifetime Medicaid revenue is $5.9M compared with $1.9M in Medicare, so Medicaid represents the larger revenue stream for this provider and likely drives the bulk of testing volume and contractual relationships with payers and facilities.
Competitive standing for key Medicare codes is above typical national volumes: G0483 ranks #50 of 1063 providers nationally (95th percentile) and 82306 and 80307 rank in the high national percentiles (99th and 98th respectively), which indicates stronger-than-average national presence on those tests even as descriptions continue to label the volumes as typical for the code.
State-level position in Medicaid is often leading for priority services: the provider ranks #3 of 15 in-state for U0004 (86th percentile) and is #1 of 22 in-state for G0483 (100th percentile; described as notably above typical state volume), signaling it is a major in-state supplier for COVID and definitive toxicology testing.
Operational footprint includes substantial specimen-collection activity: Medicare shows 104.6K claims for P9603 with $104.6K revenue (6.2% of Medicare revenue), which reflects a high volume of billed travel allowance/specimen collection events and suggests an active home‑bound or nursing‑home specimen collection service line.
Certain codes are state outliers for specific services: on Medicaid the provider is notably above typical state volume for G0483 (listed as 100th percentile) and 87500 ranks #2 of 15 in-state (93th percentile; described as notably above typical state volume), reinforcing that drug-testing and select molecular resistance assays are areas of above‑average in‑state concentration.
Tenure and operating history are recent but established: the NPI was enumerated 2018-01-26 (~8 years ago), indicating the lab has built substantial Medicaid and Medicare billing volume within a relatively short operating window since enumeration.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
96 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,990 | $240 | $480.4K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 4,240 | $30 | $123.1K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2,010 | $60 | $122.9K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 3,310 | $30 | $112.4K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 6,650 | $20 | $106.4K |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 104,560 | $1 | $104.6K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 9,620 | $10 | $96.2K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 6,470 | $10 | $84.1K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 9,860 | $10 | $69K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 7,400 | $10 | $59.2K |
Showing 1–10 of 96
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 96 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
127 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 28,980 | $50 | $1.5M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 9,360 | $90 | $795.2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 7,450 | $80 | $588.8K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 23,020 | $20 | $437.3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 20,550 | $20 | $308.3K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 2,580 | $90 | $224.4K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 19,950 | $10 | $199.4K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 7,500 | $30 | $194.9K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 6,400 | $20 | $134.4K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 6,160 | $20 | $117K |
Showing 1–10 of 127
How this provider's Medicaid billing volume and revenue compare to other Alabama providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Alabama median
127 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 3 | 10 | 1,190 | $1,590 | $67M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 14 | 60 | 1,260 | $60 | $1.2M |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 37 | 100 | 470 | $130 | $1.2M |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 3 | 20 | 160 | $20 | $1.1M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 3 | 20 | 10,040 | $40 | $825.9K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 11 | 40 | 450 | $20 | $591.3K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 9 | 40 | 460 | $20 | $584.1K |
| 86480 | The lab analyst performs a test to evaluate a cell mediated immunity gamma interferon antigen response to certain tuberculosis, or TB, antibodies. | 3 | 10 | 240 | $30 | $448.2K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 17 | 40 | 1,540 | $10 | $397.4K |
| 87389 | The lab analyst performs a test to screen for human immunodeficiency virus, called HIV. The test screens for antigens of the HIV 1 virus and antibodies to the HIV 1 and HIV 2 viruses using an… | 11 | 40 | 430 | $10 | $391.5K |
Showing 1–10 of 127
Other providers in the same ZIP code as Devansh Lab Werks,inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Core Diagnostic Laboratories LLC | AL | Clinical Medical Laboratory | $1.3M | $44.2M |
| Lab Works, LLC | AL | Clinical Medical Laboratory | $738.4K | $41.6M |
| Valentines Home Care, Inc. | AL | Durable Medical Equipment & Medical Supplies | $0 | $13.6M |
| Grayson And Associates PC | AL | Psychiatry Physician | $0 | $5M |
| Affinity Acquisitions, LLC | AL | Community Based Hospice Care Agency | $0 | $4.8M |
| Metro Pediatrics PC | AL | Specialist | $0 | $4.5M |
| Birmingham Radiological Group PC | AL | Diagnostic Radiology Physician | $0 | $3.5M |
| Proteus Molecular And Clinical Lab LLC | AL | Clinical Medical Laboratory | $236.9K | $3.2M |
| Greg Eudy | AL | Rheumatology Physician | $3.3M | $0 |
| Luigi Bertoli | AL | Hematology (Internal Medicine) Physician | $2.8M | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.